助研究員

---

CMHU1220
02-2789-8777

 

EDUCATION AND POSITIONS HELD:

• Ph.D., Institute of Biochemistry and Molecular Biology, National Taiwan University, College of Medicine, 2010
• Postdoctoral Fellow, Institute of Biochemistry and Molecular Biology, National Yang-Ming University, 2010-2012
• Postdoctoral Fellow, Department of Biological Chemistry, School of Medicine, University of California, Irvine, USA, 2012-2013
• Postdoctoral Fellow, Genomics Research Center, Academia Sinica, 2013-2014
• Regular Postdoctoral Fellow, Academia Sinica, 2014
• Assisant Research Specialist, Genomics Research Center, Academia Sinica, 2014-2019
• Assisant Professor, Genomics Research Center, Academia Sinica, 2019-present

HONORS:

• Award for Excellent Ph.D. Thesis from the Chien-Tien Hsu Cancer Research Foundation at the 7th Symposium on Recent Advances in Cellular and Molecular Biology, 1999
• Excellence Award The first session of the Merck Award for young biotech, 2008
• Excellence Award National Taiwan University Graduate Award for outstanding work, 2008

EXPERTISE:

• Nucleotide metabolism and genomic instability studies
• Tumorigenic activity assay (including the determination of growth rate, mutation rate, soft-agar colony formation and tumorigenecity in nude/scid mice).
• Polyclonal antibody generation
• Develop method for high-throughput drug screening
• Identify small molecules for targeted therapy
• Uncover drug action mechanism

我的研究工作主要是從核酸代謝的角度去探討癌症的生成，進一步去建立高速篩選小分子藥物方法，辨別並分析藥物的作用效力與機制，以達到治療和預防癌症的目的。

PATENTS

• Chang ZF, Fang JM, Hu CM, Yeh MT. Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells. US20130252953 A1, CN103476411A, WO2012072019A1. 2013
• Lee WH, Zhu J, Qiu XL, Hu CM. Small Molecule Modifiers of The Hec1-Nek2 Interaction In G2/M. UC2013-847-1

SELECTED PUBLICATIONS:

• Tien SC, Shih M and Hu CM*, accepted, “Inhibition of RRM1 O-GlcNAcylation suppresses pancreatic cancer via TK1 stabilization-induced replication stress”, Cancer Gene Therapy. (SCIE)
• Hu CM*, Tien SC, Lo YC, Huang CH, Ko YL, Wu DN, Lee JH, Wu YT, Yu HM, Ling KG, Lee ZY, and Cheng WC, 2025, “Novel cyclic peptide disrupts the IL-17RB/MLK4 interaction for targeted therapy of pancreatic cancer”, Biomedicine & Pharmacotherapy, 184, 117892. (SCIE)
• Tien SC, Chang CC, Huang CH, Peng HY, Chang YT, Chang MC, Lee WH, Hu CM, 2024, “Exosomal miRNA 16-5p/29a-3p from pancreatic cancer induce adipose atrophy by inhibiting adipogenesis and promoting lipolysis.”, iScience, 27, 110346. (SCIE)
• Chen YI, Tien SC, Ko YL, Chang CC, Hsu MF, Chien HJ, Peng HY, Jeng YM, Tien YW, Chang YT, Chang MC, Hu CM*, 2024, “SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front.”, Cancer gene therapy, 31, 1840-1855. (SCIE)
• Chen Wei‐Ju, Huang Wei‐Kai, Pather Sarshan R., Chang Wei‐Fang, Sung Li‐Ying, Wu Han‐Chung, Liao Mei‐Ying, Lee Chi‐Chiu, Wu Hsuan‐Hui, Wu Chung‐Yi, Liao Kuo‐Shiang, Lin Chun‐Yu, Yang Shang‐Chih, Lin Hsuan, Lai Pei‐Lun, Ng Chi‐Hou, Hu Chun‐Mei, Chen I‐Chih, Chuang Chi‐Hsuan, Lai Chien‐Ying, Lin Po‐Yu, Lee Yueh‐Chang, Schuyler Scott C., Schambach Axel, Lu Frank Leigh, Lu Jean, 2023, “Podocalyxin‐Like Protein 1 Regulates Pluripotency through the Cholesterol Biosynthesis Pathway”, Advanced Science, 10(1), 2205451. (SCIE)
• Hu CM, Huang CC, Hsu MF, Chien HJ, Wu PJ, Chen YI, Jeng YM, Tang SC, Chung MH, Shen CN, Chang MC, Chang YT, Tien YW, Lee WH, 2023, “Oncogenic KRAS, Mucin 4, and Activin A-Mediated Fibroblast Activation Cooperate for PanIN Initiation.”, Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 2301240, 1-20. (SCIE)
• Chang YT, Peng HY, Hu CM, Tien SC, Chen YI, Jeng YM, Chang MC, 2023, “Pancreatic cancer-derived small extracellular vesical ezrin activates fibroblasts to exacerbate cancer metastasis through STAT3 and YAP-1 signaling pathways.”, Molecular Oncology, 17, 1628-1647. (SCIE)
• Chen Jia-Yang, Chou Hsu-Huan, Lim Syer Choon, Huang Yen-Jang, Lai Kuan-Chen, Guo Chin-Lin, Tung Chien-Yi, Su Chung-Tsai, Wang Jocelyn, Liu Edward, Han Hsiao-Fen, Yeh Po-Ying, Hu Chun-Mei, Dunn Alexander R., Frank Curtis W., Wu Yi-Chun, Yang Muh-Hwa, Chang Ying-Chih, 2022, “Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine”, iScience, 25(10), 105081. (SCIE)
• Lee Wen-Hsin, Chen Xiaorui, Liu I-Ju, Lee Jiin-Horng, Hu Chun-Mei, Wu Han-Chung, Wang Sheng-Kai, Lee Wen-Hwa, Ma Che, 2022, “Structural basis of interleukin-17B receptor in complex with a neutralizing antibody for guiding humanization and affinity maturation”, Cell Reports, 41(4), 111555. (SCIE)
• Hsu YS, Wu PJ, Jeng YM, Hu CM*, Lee WH*., 2022, “Differential Effects of Glucose and N-acetylglucosamine on Genome instability.”, Am J Cancer Res, 12(4), 1556-1567. (SCIE)
• Chen YI, Chang CC, Hsu MF, Jeng YM, Tien YW, Chang MC, Chang YT, Hu CM, Lee WH, 2022, “Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation.”, Nature communications, 13, 2945. (SCIE)
• Liu Yu-Huei, Hu Chun-Mei, Hsu Yuan-Sheng, Lee Wen-Hwa, 2022, “Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma”, Cell Death & Disease, 13(9), 817-826. (SCIE)
• 1.Wu HH, Tsai LH, Huang CK, Hsu PH, Chen MY, Chen YI, Hu CM, Shen CN, Lee CC, Chang MC, Chang YT, Tien YW, Jeng YM, Lee EYP, Lee WH, 2021, “Characterization of Initial Key Steps of IL-17 Receptor B Oncogenic Signaling for Targeted Therapy of Pancreatic Cancer”, Science Translational Medicine, 13(583), eabc2823. (SCIE)
• Su FY, Hung SC, Wei PC, Su LW, Hsu PH, Li JP, Lan JL, Hsieh YL, Hu CM, Chun CY, Sytwu HK, Lee EY and Lee WH., 2021, “Redox sensor NPGPx restrains ZAP70 activity and modulates T cell homeostasis”, Free Radical Biology and Medicine, 165, 368-384. (SCIE)
• Hsu JL, Chou JW, Su FY, Lan JL, Wu PC, Hu CM, Lee EY and Lee WH*, 2020, “Glutathione peroxidase 8 negatively regulates caspase-4/11 to protect against colitis.”, EMBO MOLECULAR MEDICINE, 12, e9386. (SCIE)
• Hsieh YL, Tsai LK, Su FY, Tsai YC, Ko YL, Hu CM, Hsiu-Ming Shih and Lee WH*., 2019, “NPGPx-Mediated Adaptation to Oxidative Stress Protects Motor Neurons from Degeneration in Aging by Directly Modulating O-GlcNAcase”, CELL REPORTS, 29, 2134-2143. (SCIE)
• Hu CM*, Tien SC, Hsieh PK, Jeng YM, Chang MC, Chang YT, Chen YJ, Chen YJ, Lee EY and Lee WH, 2019, “High glucose triggers nucleotide imbalance through O-GlcNAcylation of key enzymes and induces KRAS mutation in pancreatic cells”, CELL METABOLISM, 29, 1334-1349. (SCIE)
• Chen YL, Hu CM, Hsu JT, Chang CC, Huang TY, Chiang PH, Chen WY, Chang YT, Chang MC, Tien YW, Lee EY, Jeng YM and Lee WH, 2018, “Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma”, American journal of cancer research., 8, 2548-2563. (SCIE)
• Huang SC, Wei PC, Hwang-Verslues WW, Kuo WH, Jeng YM, Hu CM, Shew JY, Huang CS, Chang KJ, Lee EY and Lee WH, 2017, “TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB.”, EMBO molecular medicine, 9, 1660-1680. (SCIE)
• Huang CK, Chang PH, Kuo WH, Chen CL, Jeng YM, Chang KJ, Shew JY, Hu CM and Lee WH., 2017, “Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate.”, nature communications, 8, 14706. (SCIE)
• Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, Kim Y, Lopez R, Chamberlin AR, Lee EH, Lee WH., 2015, “Novel small molecules disrupting Hec1/Nek2 interaction ablates tumor progression by triggering Nek2 degradation through a death-trap mechanism.”, ONCOGENE, 34(10), 1220-1230. (SCIE)
• Ngo B, Hu CM, Guo XE, Ngo B, Wei R, Zhu J and Lee WH., 2013, “Complementary interhelical interactions between three buried Glu-Lys pairs within three heptad repeats are essential for Hec1-Nuf2 heterodimerization and mitotic progression.”, JOURNAL OF BIOLOGICAL CHEMISTRY, 288, 34403-34413. (SCIE)
• Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G, Qiu XL, Chen CF, Hu CM, Goldblatt E, Bhatia R, Chamberlin AR, Chen PL, Lee WH. , 2013, “A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.”, EMBO Molecular Medicine, 5, 353-365. (SCIE)
• Hu CM, Yeh MT, Tsao N, Chen CW, Gao QZ, Chang CY, Lee MH, Fang JM, Sheu SY, Lin CJ, Tseng MC, Chen YJ, Chang ZF, 2012, “Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair.”, CANCER CELL, 22, 36-50. (SCIE)
• Hu CM, Chang ZF , 2010, “A bioluminescent method for measuring thymidylate kinase activity suitable for high-throughput screening of inhibitor.”, ANALYTICAL CHEMISTRY, 398(2), 269-271. (SCIE)
• Hu CM, Chang ZF., 2008, “Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status.”, CANCER RESEARCH, 68(8), 2831-2840. (SCIE)
• Hu CM, Chang ZF, 2007, “Mitotic control of dTTP pool: a necessity or coincidence? ”, JOURNAL OF BIOMEDICAL SCIENCE, 14(4), 491-497. (SCIE)
• Ke PY, Hu CM, Chang YC, Chang ZF. , 2007, “Hiding human thymidine kinase 1 from APC/C- mediated destruction by thymidine binding.”, FASEB JOURNAL, 21, 1276-1284. (SCIE)
• Ke PY, Kuo YY, Hu CM, Chang ZF., 2005, “Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. ”, GENES & DEVELOPMENT, 19, 1920-1933. (SCIE)